orforglipron
orforglipron is listed in the FDA National Drug Code directory with 26 NDC codes, marketed under brand name including FOUNDAYO. Available dosage forms: tablet, film coated, capsule.
Drug Details
- Generic Name
- orforglipron
- Brand Names
- FOUNDAYO
- Application Number
- NDA220934
- Sponsor
- Pfizer Italia S.r.l.
- NDC Codes
- 26
- Dosage Forms
- TABLET, FILM COATED, CAPSULE
- Routes
- ORAL
- Active Ingredients
- ORFORGLIPRON CALCIUM
Indications and Usage
1 INDICATIONS AND USAGE FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended.